Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma
| Autor: | D. J. Richel, Wim E. Fibbe, M. van Marwijk Kooy, A. W. Dekker, Alexandra J. Croockewit, H. C. Schouten, Edo Vellenga, J. J. Cornellissen, Pieter Sonneveld, Bob Löwenberg, H. M. Lokhorst, P. W. Wijermans, S. Wittebol, Christine M. Segeren, M. H. J. Van Oers, Gregor Verhoef, Douwe H. Biesma, B. van der Holt, Joke W. Baars |
|---|---|
| Přispěvatelé: | Other departments, Hematology, Cardiology |
| Rok vydání: | 1999 |
| Předmět: |
medicine.medical_specialty
Vincristine medicine.drug_class medicine.medical_treatment COMBINATION CHEMOTHERAPY chemotherapy THERAPY Gastroenterology Molecular pathogenesis of multiple myeloma Moleculaire pathogenese van het multipele myeloom loom (MM) Internal medicine medicine ADRIAMYCIN Multiple myeloma Dexamethasone Chemotherapy business.industry Combination chemotherapy rapid infusion Hematology medicine.disease multiple myeloma induction treatment Regimen VAD Anesthesia Toxicity Corticosteroid business medicine.drug |
| Zdroj: | British journal of haematology, 105(1), 127-130. Wiley-Blackwell British Journal of Haematology, 105, pp. 127-130 British Journal of Haematology, 127-130 STARTPAGE=127;ENDPAGE=130;ISSN=0007-1048;TITLE=British Journal of Haematology British Journal of Haematology, 105, 127-130. Wiley-Blackwell Publishing Ltd British Journal of Haematology, 105(1), 127-130. Wiley |
| ISSN: | 0007-1048 |
| Popis: | Contains fulltext : 188587.pdf (Publisher’s version ) (Closed access) We examined the feasibility of achieving a rapid response in patients with previously untreated multiple myeloma by administering vincristine 0.4 mg and doxorubicin 9 mg/m2 as a rapid intravenous infusion for 4d together with intermittent high-dose dexamethasone 40 mg (VAD) for remission induction treatment in patients who were scheduled to receive high-dose therapy. 139 patients (86 male, 53 femaile; median age 53 years, range 32-65 years; Durie & Salmon stage IIA: 42, IIB: one IIIA: 89, IIIB: seven) were included in a prospective multicentre study in which VAD was administered as remission induction treatment and was followed by intensified treatment. The response was evaluated according to the criteria of the Eastern Cooperative Oncology Group (ECOG). The results of treatment were evaluable in 134 patients. Five patients died before evaluation. 86 patients (62%) achieeved a partial response (PR) and seven patients (5%) achieved a complete response (CR), which equates to a response rate of 67%. The main side-effect was milt neurotoxicity, which was observed in 18% of the patients. Fever or infections were reported in 27% of the patients. VAD administered as an outpatient regimen, based on rapid intravenous infusion, is an effective induction regimen for untreated myeloma with a 67% response rate and acceptable toxicity |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text